Breaking The Biomanufacturing Mold: A Patient-Centric CDMO Approach

As biopharmaceutical programs progress from early clinical development to commercial manufacturing, viral clearance studies evolve from set-point evaluations to complex, worst-case oriented validations designed to assure patient safety and meet regulatory expectations. Early studies focus on controlled conditions with limited parameter knowledge, while late-stage programs require extensive process characterization to define and test conditions that represent the lowest plausible viral clearance. Key challenges include long wet-lab timelines, unexpected study outcomes, defining worst-case ranges, scale-up effects, the added complexity of non-mAb modalities, and coordination across multi-site operations. A robust late-stage strategy typically combines viral inactivation and filtration with orthogonal chromatography steps, augmented by increasingly sensitive analytical methods (e.g., qPCR, with growing interest in NGS) and alignment to regional guidelines (e.g., ICH Q5A(R2), EMA). Collaborative partnerships with experienced CDMOs are critical to mitigate risk, conduct feasibility and developmental studies (including surrogate models), and tailor approaches for complex molecules such as bispecifics. FUJIFILM Biotechnologies supports end-to-end execution via its kojoX™ network and global sites, integrating preparatory testing, bridging runs, and late-stage studies alongside process validation and PPQ. This iterative, lifecycle-driven approach de-risks development, maintains compliance amid process changes, and accelerates the path to commercialization while safeguarding product quality and patient safety. Download the white paper to learn more.